NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet]. York (UK): Centre for Reviews and Dissemination (UK); 1995-.
Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet].
Show detailsBibliographic details: Keefe RS, McClintock SM, Roth RM, Doraiswamy PM, Tiger S, Madhoo M. Cognitive effects of pharmacotherapy for major depressive disorder: a systematic review. Journal of Clinical Psychiatry 2014; 75(8): 864-876. [PubMed: 25099527]
Abstract
OBJECTIVE: Cognitive impairment frequently accompanies major depressive disorder (MDD) and can persist during remission. This review examined pharmacotherapy effects on cognitive function in MDD.
DATA SOURCES: PubMed and EMBASE searches were conducted on July 30, 2013, for English language reports of cognitive assessments following pharmacologic monotherapy or augmentation therapy in MDD.
STUDY SELECTION: A total of 43 research reports were identified (31 monotherapy [8 placebo-controlled, 11 active-comparator, 12 open-label], 12 augmentation therapy [7 placebo-controlled, 5 open-label]).
DATA EXTRACTION: Results reported in each publication were examined for open-label and placebo- or active comparator-controlled studies.
RESULTS: Studies varied widely in terms of size (median, 50 participants; interquartile range, 21-143 participants), populations examined, duration (median, 8 weeks; interquartile range, 6-12 weeks), and neurocognitive assessments used. Most individual studies reported some benefit to cognition with pharmacotherapy, but there was no pattern of response in specific domains and only 12% of individually analyzed changes favored active treatment over placebo or untreated healthy controls. Sample weighted mean effect sizes revealed that verbal memory improved with monotherapy, while the largest treatment effect with augmentation therapy was for visual memory.
CONCLUSIONS: Pharmacotherapy may have benefit in reducing cognitive impairment in MDD, with augmentation therapy being a potential approach for addressing cognitive deficits that persist after monotherapy has brought about clinical response or remission. However, given the wide variability in study design and treatment duration across studies, these findings should be interpreted cautiously. More definitive research is required before firm conclusions can be reached.
© Copyright 2014 Physicians Postgraduate Press, Inc.
- Review Cognitive dysfunction in unipolar depression: implications for treatment.[J Affect Disord. 2014]Review Cognitive dysfunction in unipolar depression: implications for treatment.Trivedi MH, Greer TL. J Affect Disord. 2014 Jan; 152-154:19-27. Epub 2013 Sep 25.
- Review Pharmacological Treatment of Cognitive Symptoms in Major Depressive Disorder.[CNS Neurol Disord Drug Targets...]Review Pharmacological Treatment of Cognitive Symptoms in Major Depressive Disorder.Pan Z, Grovu RC, Cha DS, Carmona NE, Subramaniapillai M, Shekotikhina M, Rong C, Lee Y, McIntyre RS. CNS Neurol Disord Drug Targets. 2017; 16(8):891-899.
- Review Cognitive remission: a novel objective for the treatment of major depression?[BMC Med. 2016]Review Cognitive remission: a novel objective for the treatment of major depression?Bortolato B, Miskowiak KW, Köhler CA, Maes M, Fernandes BS, Berk M, Carvalho AF. BMC Med. 2016 Jan 22; 14:9. Epub 2016 Jan 22.
- Procognitive Effects of Antidepressants and Other Therapeutic Agents in Major Depressive Disorder: A Systematic Review.[J Clin Psychiatry. 2020]Procognitive Effects of Antidepressants and Other Therapeutic Agents in Major Depressive Disorder: A Systematic Review.Blumberg MJ, Vaccarino SR, McInerney SJ. J Clin Psychiatry. 2020 Jul 21; 81(4). Epub 2020 Jul 21.
- Review Does the presence of an open-label antidepressant treatment period influence study outcome in clinical trials examining augmentation/combination strategies in treatment partial responders/nonresponders with major depressive disorder?[J Clin Psychiatry. 2012]Review Does the presence of an open-label antidepressant treatment period influence study outcome in clinical trials examining augmentation/combination strategies in treatment partial responders/nonresponders with major depressive disorder?Iovieno N, Papakostas GI. J Clin Psychiatry. 2012 May; 73(5):676-83. Epub 2012 Apr 3.
- Cognitive effects of pharmacotherapy for major depressive disorder: a systematic...Cognitive effects of pharmacotherapy for major depressive disorder: a systematic review - Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews
Your browsing activity is empty.
Activity recording is turned off.
See more...